01502nas a2200349   4500000000100000008004100001260000900042653001000051653001600061653001200077653003000089653001100119653001100130653001200141653002400153653002500177653000900202653001600211653001300227100000900240700000900249700001100258700001000269700001000279700001100289700000900300245007900309300001000388490000600398520073400404022001401138       1990                            d  c199010aAdult10aClofazimine10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aleprosy10aLeprosy, Borderline10aLeprosy, lepromatous10aMale10aMiddle Aged10aRifampin1 aLi W1 aYe G1 aYang Z1 aTao M1 aLuo J1 aWang C1 aJi F00aEffect of three-year multidrug therapy in multibacillary leprosy patients.  a37-400 v53 a<p>The feasibility and effects of a 3-year treatment using rifampicin (RFP), clofazimine (B663) and dapsone (DDS) in multibacillary leprosy patients in Yangzhou Prefecture and Dongtai County (1983-1986) are reported. Among 591 active multibacillary leprosy patients in the two areas, 569 (96.30%) were treated with this regimen. Of 303 cases available for analysis, 196 (64.7%) cases showed negative skin smears and clinical inactivity. The rest showed different degrees of improvement. The average reduction of BI was 0.78. The intensity and frequency of ENL and neuritis decreased markedly with treatment. The main side-effects were pigmentation and ichthyosiform changes of the skin, but these did not influence treatment.</p>  a0258-8757